Cipla Gets FDA Approval For Generic Nintedanib Capsules

Cipla USA, a wholly owned subsidiary of Cipla Limited, received U.S. FDA final approval for an ANDA for Nintedanib Capsules, 100 mg and 150 mg. The approval permits Cipla to market a generic version of nintedanib in the U.S. for the treatment of Idiopathic Pulmonary (as stated), expanding its product portfolio in respiratory care. Impact is likely modest and company-specific, potentially supporting incremental U.S. sales rather than driving sector-wide moves.

Analysis

Cipla USA, a wholly owned subsidiary of Cipla Limited, received U.S. FDA final approval for an ANDA for Nintedanib Capsules, 100 mg and 150 mg. The approval permits Cipla to market a generic version of nintedanib in the U.S. for the treatment of Idiopathic Pulmonary (as stated), expanding its product portfolio in respiratory care. Impact is likely modest and company-specific, potentially supporting incremental U.S. sales rather than driving sector-wide moves.